Humacyte, Inc. (NASDAQ: HUMA) is a Healthcare company (Biotechnology) with a market capitalization of $139M. The Maz Rating grades it against the other companies in its sector.
Humacyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.50, Humacyte, Inc. trades at 58.7x sales and 7.8x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $126M. It runs a gross margin of -549.7%, an operating margin of -4602.9% and a net margin of -3955.1%. It shows return on equity of -591.7%, return on invested capital of -109.4% and a free cash flow yield of -63.1%. On the balance sheet: a debt-to-equity ratio of 3.65 and a current ratio of 3.34. Over the past 52 weeks the share price ranged from $0.34 to $1.53, with a beta of 2.68.
Humacyte, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Humacyte, Inc. (HUMA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 29.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 51.2% / 30% · Interest income / Revenue 58.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 29.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 51.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 58.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 29.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 51.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 58.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 29.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 49.6% / 33.33% · Receivables / Avg Assets (4Q) 0.25% / 33.33% · Interest income / Revenue 58.5% / 5% | Fail |
| FTSE | Debt / Total Assets 29.3% / 33.33% · (Cash+ST Inv) / Total Assets 51.4% / 33.33% · (Cash+Recv) / Total Assets 51.4% / 33.33% · Interest income / Revenue 58.5% / 5% | Fail |
No. As of September 2026, Humacyte, Inc. (HUMA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Humacyte, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 58.5% of each dividend: Humacyte, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.